MA Boston의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 45개가 Boston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
피험자 모집 중3상
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
피험자 모집 중1상
- Dana Farber/Harvard Cancer Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
피험자 모집 중3상
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
피험자 모집 중4상
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
피험자 모집 중관찰 연구
- Massachussetts General Hospital, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
피험자 모집 중1상
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
피험자 모집 중1/2상
- Research Site, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
피험자 모집 중3상
- Boston Medical Center, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
피험자 모집 중1/2상
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
피험자 모집 중1상
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
피험자 모집 중3상
- Research Site, Boston
- Research Site, Boston
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
피험자 모집 중3상
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
피험자 모집 중1/2상
- Research Site, Boston
- Research Site, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
피험자 모집 중3상
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- Tufts Medical Center, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- Mass General Brigham, Boston
ELISA in Relapsed/Refractory MM
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Elranatamab in R/R Multiple Myeloma
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1상
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
피험자 모집 중1상
- Massachusetts General Hospital, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
피험자 모집 중3상
- Tufts Medical Center, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
피험자 모집 중1/2상
- GSK Investigational Site, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
피험자 모집 중1/2상
- Boston Medical Center, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
피험자 모집 중2상
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
피험자 모집 중1/2상
- Dana Farber Cancer Institute, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
피험자 모집 중
- Dana-Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
피험자 모집 중
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
피험자 모집 중1상
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
피험자 모집 중
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
피험자 모집 중관찰 연구
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- Dana-Farber Cancer Institute, Boston
다른 도시의 다발성 골수종 시험
- New York City, NY연구 59개
- Atlanta, GA연구 42개
- Houston, TX연구 39개
- Durham, NC연구 36개
- Nashville, TN연구 31개
- Denver, CO연구 26개
- St. Louis, MO연구 26개
- Rochester, MN연구 25개
- Columbus, OH연구 25개
- Chicago, IL연구 24개
- Milwaukee, WI연구 23개
- Baldwin Park, CA연구 23개
Boston의 다른 연구
- 유방암연구 110개
- 암 (전체)연구 90개
- 비소세포폐암연구 87개
- 폐암연구 63개
- 대장직장암연구 62개
- 난소암연구 62개
- 전이성 암연구 61개
- 전립선암연구 56개
- 자궁내막암연구 51개
- 우울증연구 50개
- 심부전연구 46개
- 급성 골수성 백혈병연구 44개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.